

THE CORRECT ANSWER IS INDICATED WITH YELLOW HIGHLIGHTING.

- 1. The DUO-O Phase III trial is evaluating durvalumab in combination with chemotherapy/bevacizumab followed by maintenance durvalumab and olaparib/bevacizumab for patients with ovarian cancer (OC) in which disease setting?**
 - a. Newly diagnosed**
 - b. Platinum-sensitive recurrent
 - c. Platinum-resistant recurrent
- 2. What is the target of the novel antibody-drug conjugate upifitamab rilsodotin, currently under investigation for OC?**
 - a. Folate receptor alpha
 - b. NaPi2b**
 - c. Tissue factor
 - d. TROP2
- 3. Tumor treating fields (TTFields) promote antitumor activity via which of the following mechanisms?**
 - a. Enhancement of B-cell antibody production
 - b. Inhibition of folate receptor alpha signaling
 - c. Disruption of microtubules**
 - d. Inhibition of sodium-dependent phosphate transporters
- 4. Adverse events of which of the following types have been notably observed in patients receiving treatment with TTFields?**
 - a. Dermatologic**
 - b. Neurologic
 - c. Ocular
 - d. Respiratory
- 5. The ongoing GLORIOSA trial is evaluating which of the following combinations as maintenance therapy for platinum-sensitive OC?**
 - a. Durvalumab/olaparib
 - b. Rucaparib/bevacizumab
 - c. Mirvetuximab soravtansine/bevacizumab**
 - d. TTFields/olaparib